Overview

Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan

Status:
Completed

Trial end date:
2019-07-16

Target enrollment:

Participant gender:

Summary

Prospective, Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) Plus Tenofovir Disoproxil Fumarate (TDF) and Lamivudine in a Fixed-Dose Combination Tablet (Combo) for Patients Receiving Co-Formulated TDF, Emtricitabine and Efavirenz (Atripla) with Viral Suppression in Taiwan

Phase:

Phase 3

Details

Lead Sponsor:

Yu-Jay Corp.

Treatments:

Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Lamivudine